The rationale for B cell depletion therapy with rituximab in primary Sjögren's syndrome relies
upon the well-established role of B cell hyperactivity in immunopathogenesis. In line with
this notion, several biomarkers of B cell activity are significantly affected by treatment, both in
the target organs and periphery. In contrast to most biological outcomes, clinical outcomes
are not consistent between studies. Although two large RCTs did not meet their primary
endpoint, several beneficial clinical effects of treatment have been shown. As discussed in …